- Preamble [SYSTEM]
- Fund & Investor Interest
- Street Moves
- Solebury Trout Updates
- Market Commentary
- IPO News
- Expert Interactions
- Banker Comments & Notes
- Conference Snippet
- Industry Snippets
- Social Media
- Solebury Trout Talks

IPO News: Filed S-1/A: Vaxcyte Launches 14mm Share IPO with $14-$16 Marketing Range
Vaxcyte
Nasdaq: PCVX
Filing Date: 05/22/20
Launch Date: 06/08/20
Price Range: $14.00 - $16.00
Shares Offered (Pre-Shoe, mm): 14.0
Primary Shares (mm): 14.0
Secondary Shares (mm): 0.0
Amount Offered (@ Midpoint)(mm): $210.0
% Secondary: 0.0%
Shares Outstanding (mm): 46.8
Market Value at IPO Midpoint (mm): $701.4
Offering as % of Market Value: 29.9%
Bookrunners: Bank of America | Jefferies | Evercore
Co-Managers: Cantor | Needham
Major Holders: Abingworth Bioventures | Longitude Capital Partners | Roche | TPG | Frazier Life Sciences | Pivotal bioVentures | Sutro Biopharma | Medicxi Ventures | Janus Henderson | RA Capital Management
Description: Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Note: Emerging Growth Company
Reference Link: S-1/A